Complete regression of metastatic renal cell carcinoma by multiple injections of engineered mesenchymal stem cells expressing dodecameric TRAIL and HSV-TK

Clinical Cancer Research

Volumn 19, Issue 2, 2013, Pages 415-427

  Kim, Sae Won ^a   Kim, Su Jin ^a   Park, Sang Hoon ^a   Yang, Hyun Gul ^a   Kang, Moon Cheol ^a   Choi, Young Woo ^a   Kim, Seong Muk ^b   Jeun, Sin Soo ^b   Sung, Young Chul ^a  

^a Pohang University of Science and Technology (POSTECH)   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; THYMIDINE KINASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; COCULTURE; CONTROLLED STUDY; FEMALE; GENETIC ENGINEERING; HERPES SIMPLEX VIRUS; IN VITRO STUDY; IN VIVO STUDY; KIDNEY METASTASIS; LUNG METASTASIS; LUNG NODULE; MESENCHYMAL STEM CELL TRANSPLANTATION; METASTASIS INHIBITION; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; STEM CELL GENE THERAPY; SURVIVAL RATE; TUMOR REGRESSION;

ANIMALS; APOPTOSIS; CARCINOMA, RENAL CELL; DISEASE MODELS, ANIMAL; FEMALE; GENETIC THERAPY; GENETIC VECTORS; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; RATS; THYMIDINE KINASE; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSDUCTION, GENETIC;

EID: 84872518078     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-1568     Document Type: Article

References (40)

1. Ng CS, Wood CG, Silverman PM, Tannir NM, Tamboli P, Sandler CM. Renal cell carcinoma: diagnosis, staging, and surveillance. AJR Am J Roentgenol 2008;191: 1220-32.
2. Danilin S, Sourbier C, Thomas L, Lindner V, Rothhut S, Dormoy V, et al. Role of the RNA-binding protein HuR in human renal cell carcinoma. Carcinogenesis 2010;31: 1018-26.
3. Haferkamp A, Hohenfellner M. Medical treatment options in patients with metastatic renal cell carcinoma. Nephrol Dial Transplant 2007; 22: 996-9.
4. Norian LA, Kresowik TP, Rosevear HM, James BR, Rosean TR, Lightfoot AJ, et al. Eradication of metastatic renal cell carcinoma after adenovirus-encoded TNF-related apoptosis-inducing ligand (TRAIL)/ CpG immunotherapy. PLoS ONE 2012;7:e31085.
5. Haviv YS, van Houdt WJ, Lu B, Curiel DT, Zhu ZB. Transcriptional targeting in renal cancer cell lines via the human CXCR4 promoter. Mol Cancer Ther 2004;3: 687-91.
6. Merimsky O, Gez E, Weitzen R, Nehushtan H, Rubinov R, Hayat H, et al. Targeting pulmonary metastases of renal cell carcinoma by inhalation of interleukin-2. Ann Oncol 2004;15: 610-2.
7. Albiges L, Oudard S, Negrier S, Caty A, Gravis G, Joly F, et al. Complete remission with tyrosine kinase inhibitors in renal cell carcinoma. J Clin Oncol 2012;30: 482-7.
8. Galderisi U, Giordano A, Paggi MG. The bad and the good of mesenchymal stem cells in cancer: boosters of tumor growth and vehicles for targeted delivery of anticancer agents. World J Stem Cells 2010;2: 5-12.
9. Seo SH, Kim KS, Park SH, Suh YS, Kim SJ, Jeun SS, et al. The effects of mesenchymal stem cells injected via different routes on modified IL-12-mediated antitumor activity. Gene Ther 2011; 18: 488-95.
10. Gao P, Ding Q, Wu Z, Jiang H, Fang Z. Therapeutic potential of human mesenchymal stem cells producing IL-12 in a mouse xenograft model of renal cell carcinoma. Cancer Lett 2010;290: 157-66.
11. Hsiao WC, Sung SY, Liao CH, Wu HC, Hsieh CL. Vitamin D3-inducible mesenchymal stem cell-based delivery of conditionally replicating adenoviruses effectively targets renal cell carcinoma and inhibits tumor growth. Mol Pharm 2012;9: 1396-408.
12. Rath P, Shi H, Maruniak JA, Litofsky NS, Maria BL, Kirk MD. Stem cells as vectors to deliver HSV/tk gene therapy for malignant gliomas. Curr Stem Cell Res Ther 2009;4: 44-9.
13. Amm HM, Zhou T, Steg AD, Kuo H, Li Y, Buchsbaum DJ. Mechanisms of drug sensitization to TRA-8, an agonistic death receptor 5 antibody, involve modulation of the intrinsic apoptotic pathway in human breast cancer cells. Mol Cancer Res 2011;9: 403-17.
14. Lim SM, Kim TH, Jiang HH, Park CW, Lee S, Chen X, et al. Improved biological half-life and anti-tumor activity of TNF-related apoptosisinducing ligand (TRAIL) using PEG-exposed nanoparticles. Biomaterials 2011;32: 3538-46.
15. Lee J, Hampl M, Albert P, Fine HA. Antitumor activity and prolonged expression from a TRAIL-expressing adenoviral vector. Neoplasia 2002;4: 312-23.
16. Loebinger MR, Eddaoudi A, Davies D, Janes SM. Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res 2009;69: 4134-42.
17. Nagane M, Shimizu S, Mori E, Kataoka S, Shiokawa Y. Predominant antitumor effects by fully human anti-TRAIL-receptor 2 (DR5) monoclonal antibodies in human glioma cells in vitro and in vivo. Neuro Oncol 2010;12: 687-700.
18. Allen JE, Ferrini R, Dicker DT, Batzer G, Chen E, Oltean DI, et al. Targeting TRAIL death receptor 4 with trivalent DR4 atrimer complexes. Mol Cancer Ther 2012;11: 2087-95.
19. Kaliberov SA, Chiz S, Kaliberova LN, Krendelchtchikova V, Della Manna D, Zhou T, et al. Combination of cytosine deaminase suicide gene expression with DR5 antibody treatment increases cancer cell cytotoxicity. Cancer Gene Ther 2006;13: 203-14.
20. Beltinger C, Fulda S, Walczak H, Debatin KM. TRAIL enhances thymidine kinase/ganciclovir gene therapy of neuroblastoma cells. Cancer Gene Ther 2002;9: 372-81.
21. Cozar JM, Aptsiauri N, Tallada M, Garrido F, Ruiz-Cabello F. Late pulmonary metastases of renal cell carcinoma immediately after posttransplantation immunosuppressive treatment: a case report. J Med Case Rep 2008;2:111.
22. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999;5: 157-63.
23. Park SH, Doh J, Park SI, Lim JY, Kim SM, Youn JI, et al. Branched oligomerization of cell-permeable peptides markedly enhances the transduction efficiency of adenovirus into mesenchymal stem cells. Gene Ther 2010;17: 1052-61.
24. Inoue Y, Izawa K, Kiryu S, Tojo A, Ohtomo K. Diet and abdominal autofluorescence detected by in vivo fluorescence imaging of living mice. Mol Imaging 2008;7: 21-7.
25. Szegezdi E, O'Reilly A, Davy Y, Vawda R, Taylor DL, Murphy M, et al. Stem cells are resistant to TRAIL receptor-mediated apoptosis. J Cell Mol Med 2009;13: 4409-14.
26. Matuskova M, Hlubinova K, Pastorakova A, Hunakova L, Altanerova V, Altaner C, et al. HSV-tk expressing mesenchymal stem cells exert bystander effect on human glioblastoma cells. Cancer Lett 2010;290: 58-67.
27. Wolf D, Rumpold H, Koeck R, Gunsilius E. Re: Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst 2005;97: 540-1.
28. Cho IC, Chung J. Current status of targeted therapy for advanced renal cell carcinoma. Korean J Urol 2012;53: 217-28.
29. Pavet V, Beyrath J, Pardin C, Morizot A, Lechner MC, Briand JP, et al. Multivalent DR5 peptides activate the TRAIL death pathway and exert tumoricidal activity. Cancer Res 2010;70: 1101-10.
30. Haswell LE, Glennie MJ, Al-Shamkhani A. Analysis of the oligomeric requirement for signaling by CD40 using soluble multimeric forms of its ligand, CD154. Eur J Immunol 2001;31: 3094-100.
31. Li J, WangK, Jensen TD, Li S, Bolund L, Wiuf C. Tumor heterogeneity in neoplasms of breast, colon, and skin. BMC Res Notes 2010;3:321.
32. Ma S, Chan KW, Hu L, Lee TK, Wo JY, Ng IO, et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 2007;132: 2542-56.
33. Nishizawa S, Hirohashi Y, Torigoe T, Takahashi A, Tamura Y, Mori T, et al. HSP DNAJB8 controls tumor-initiating ability in renal cancer stem-like cells. Cancer Res 2012;72: 2844-54.
34. Hu W, Liu W. Side populations of glioblastoma cells are less sensitive to HSV-TK/GCV suicide gene therapy system than the non-side population. In Vitro Cell Dev Biol Anim 2010;46: 497-501.
35. Sussman RT, Ricci MS, Hart LS, Sun SY, El-Deiry WS. Chemotherapy- resistant side-population of colon cancer cells has a higher sensitivity to TRAIL than the non-SP, a higher expression of c-Myc and TRAIL-receptor DR4. Cancer Biol Ther 2007;6: 1490-5.
36. Zhang X, Komaki R, Wang L, Fang B, Chang JY. Treatment of radioresistant stem-like esophageal cancer cells by an apoptotic genearmed, telomerase-specific oncolytic adenovirus. Clin Cancer Res 2008;14: 2813-23.
37. Rainov NG, Kramm CM, Banning U, Riemann D, Holzhausen HJ, Heidecke V, et al. Immune response induced by retrovirus-mediated HSV-tk/GCV pharmacogene therapy in patients with glioblastoma multiforme. Gene Ther 2000;7: 1853-8.
38. Saati S, Agrawal RN, Louie S, Chader GJ, Humayun MS. Effect of multiple injections of small divided doses vs single injection of intravitreal bevacizumab on retinal neovascular model in rabbits. Graefes Arch Clin Exp Ophthalmol 2010;248: 457-66.
39. Pacciarini MA, Barbieri B, Colombo T, Broggini M, Garattini S, Donelli MG. Distribution and antitumor activity of adriamycin given in a highdose and a repeated low-dose schedule to mice. Cancer Treat Rep 1978;62: 791-800.
40. Altanerova V, CihovaM, Babic M, Rychly B, Ondicova K, Mravec B, et al. Human adipose tissue-derived mesenchymal stem cells expressing yeast cytosinedeaminase::uracil phosphoribosyltransferase inhibit intracerebral rat glioblastoma. Int J Cancer 2012; 130: 2455-63.